Prevalence of thyroid dysfunction in highly active antiretroviral therapy -Exposed people living with human immunodeficiency virus
Authors:
Open Access
- 10 June 2025
- journal article
- research article
- Published by Springer Nature in Thyroid Research
- Vol. 18 (1) , 1-9
Abstract
The incidence of thyroid dysfunction is high in HIV patients, contributing to the high mortality and morbidity associated with HIV. This study focused on evaluating the prevalence of thyroid dysfunction and associated factors among people living with HIV (PLWH) attending Comprehensive care centre at Maua Methodist Hospital, Kenya. Clinical and sociodemographic data of participants were collected including HIV viral loads, CD4 counts, HAART regimen and type, age, gender, marital and education status, and co-infection. Serum levels of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) were assessed in all groups. Regression analysis and Pearson correlation were performed to assess thyroid dysfunction and associated factors. The prevalence of thyroid dysfunction was 51.9% (95% CI: 50.8 ~ 53.2) in this population. 77% (77%) of the HAART group had thyroid dysfunction compared to 47% of the HAART naïve group. Additionally, the prevalence of thyroid dysfunction was high in the HIV-non-suppressed individuals (97%, 95% CI: 97.1 ~ 97.9) compared to suppressed group (83%, 95% CI: 82.7 ~ 84.3). HIV (p < 0.001), HAART exposure (p < 0.001), TB (p < 0.001) and duration of infection (p = 0.002) were significantly associated with thyroid dysfunction. There was a positive correlation between TSH (r = 0.28; p < 0.01) and HIV + individuals under HAART, TSH (r = 0.37; p < 0.001) and TB, and FT3 (r = 0.35; p < 0.001) and duration of infection. Additionally, there was positive corelation between thyroid dysfunction and age (r = 0.13, p = 0.13), and a negative correlation between thyroid dysfunction and CD4 counts (r = -0.39, p < 0.055) though statistically not significant. Thyroid dysfunction is more common in HIV patients on HAART, mainly manifested as subclinical hypothyroidism. Routine screening for thyroid dysfunction should be considered for PLWH, especially those on HAART and with viral blips.Keywords
Funding Information
- EDCTP2 (TMA2017-CDF-1852)
This publication has 40 references indexed in Scilit:
- Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysiseClinicalMedicine, 2020
- Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in KenyaInternational Journal of Infectious Diseases, 2020
- Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patientsScientific Reports, 2019
- Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017Nature, 2019
- Treatment for subclinical hyperthyroidism in adultsCochrane Database of Systematic Reviews, 2018
- Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet, 2016
- Highly Active Antiretroviral Therapy (HAART)2015
- Thyroid AbnormalitiesEndocrinology and Metabolism Clinics of North America, 2014
- Thyroid Function Abnormalities in HIV-Infected PatientsClinical Infectious Diseases, 2007
- Increased Prevalence of Hypothyroidism among Human Immunodeficiency Virus—Infected Patients: A Need for ScreeningClinical Infectious Diseases, 2003